Patents by Inventor Genet Zemede

Genet Zemede has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR
    Publication number: 20130244939
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: November 1, 2012
    Publication date: September 19, 2013
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
  • NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR
    Publication number: 20130012685
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: July 3, 2012
    Publication date: January 10, 2013
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, Yaohua S. Dong, David Tumelty, Guy Lalonde, Brian T. Frederick, Anjan Chakrabarti, Palani Balu, Peter J. Schatz, Nicholas C. Wrighton, William J. Dower
  • Peptides that bind to the erythropoietin receptor
    Patent number: 8304391
    Abstract: Peptide compounds that are agonists of the erythropoietin receptor (EPO-R) are described, as well as therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: November 6, 2012
    Assignee: Affymax, Inc.
    Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
  • NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR
    Publication number: 20120157660
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: August 18, 2010
    Publication date: June 21, 2012
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, David Tumelty, Guy Lalonde, Palani Balu, Peter J. Schatz, William J. Dower, Anjan Chakrabarti, Yaohua S. Dong, Brian T. Frederick, Nicholas C. Wrighton
  • NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR
    Publication number: 20110282029
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: December 10, 2010
    Publication date: November 17, 2011
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, Yaohua S. Dong, David Tumelty, Guy Lalonde, Brian T. Frederick, Anjan Chakrabarti, Palani Balu, Peter J. Schatz, Nicholas C. Wrighton, William J. Dower
  • NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR
    Publication number: 20110245176
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: November 12, 2010
    Publication date: October 6, 2011
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
  • Peptides that bind to the erythropoietin receptor
    Patent number: 7855175
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: December 21, 2010
    Assignee: Affymax, Inc.
    Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Palani Balu, Genet Zemede
  • PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR
    Publication number: 20090227508
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: March 17, 2009
    Publication date: September 10, 2009
    Applicant: Affymax, Inc.
    Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
  • Peptides that bind to the erythropoietin receptor
    Patent number: 7528104
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Grant
    Filed: May 12, 2004
    Date of Patent: May 5, 2009
    Assignee: Affymax, Inc.
    Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
  • NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR
    Publication number: 20090048166
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: July 11, 2008
    Publication date: February 19, 2009
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
  • Novel Peptides that Bind to the Erythropoietin Receptor
    Publication number: 20090005292
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: November 11, 2005
    Publication date: January 1, 2009
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, David Tumelty, Guy Lalonde, Palani Balu, Peter J. Schatz, William J. Dower, Anjan Chakrabarti, Yaohua S. Dong, Brian T. Frederick, Nicholas C. Wrighton
  • Peptides that bind to the erythropoietin receptor
    Patent number: 7414105
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Grant
    Filed: October 27, 2005
    Date of Patent: August 19, 2008
    Assignee: Affymax, Inc.
    Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
  • NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR
    Publication number: 20080108564
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: April 13, 2007
    Publication date: May 8, 2008
    Applicant: Affymax, Inc.
    Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, Yaohua S. Dong, David Tumelty, Guy Lalonde, Brian T. Frederick, Anjan Chakrabarti, Palani Balu, Peter J. Schatz, Nicholas C. Wrighton, William J. Dower
  • Compositions and Methods for Inhibiting Cellular Proliferation
    Publication number: 20080090760
    Abstract: Compositions and methods effective in inhibiting abnormal or undesirable cell proliferation, particularly endothelial cell proliferation and angiogenesis related to neovascularization and tumor growth are provided. The compositions comprise peptide molecules, optionally containing one or more individual peptide chains covalently linked, and optionally modified with polyethylene glycol (PEG). The methods involve administering to a human or animal the composition described herein in a dosage sufficient to inhibit cell proliferation, particularly endothelial cell proliferation. The methods are useful for treating diseases and processes mediated by undesired and uncontrolled cell proliferation, such as cancer, particularly by inhibiting angiogenesis. Administration of the composition to a human or animal having prevascularized, metastasized tumors is useful for preventing the growth or expansion of such tumors.
    Type: Application
    Filed: December 8, 2006
    Publication date: April 17, 2008
    Inventors: Todd Hembrough, Christopher Holmes, Qun Yin, Genet Zemede, Yvonne Angell, Brian Frederick, Caiding Xu
  • Compositions and methods for inhibiting cellular proliferation
    Publication number: 20070203066
    Abstract: Compositions and methods effective in inhibiting abnormal or undesirable cell proliferation, particularly endothelial cell proliferation and angiogenesis related to neovascularization and tumor growth are provided. The compositions comprise peptide molecules, optionally containing one or more individual peptide chains covalently linked, and optionally modified with polyethylene glycol (PEG). The methods involve administering to a human or animal the composition described herein in a dosage sufficient to inhibit cell proliferation, particularly endothelial cell proliferation. The methods are useful for treating diseases and processes mediated by undesired and uncontrolled cell proliferation, such as cancer, particularly by inhibiting angiogenesis. Administration of the composition to a human or animal having prevascularized, metastasized tumors is useful for preventing the growth or expansion of such tumors.
    Type: Application
    Filed: December 8, 2006
    Publication date: August 30, 2007
    Inventors: Christopher Holmes, Qun Yin, Genet Zemede, Yvonne Angell, Brian Frederick, Caiding Xu
  • Novel peptides that bind to the erythropoietin receptor
    Publication number: 20070027074
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: May 12, 2004
    Publication date: February 1, 2007
    Applicant: Affymax, Inc.
    Inventors: Christopher Holmes, Qun Yin, Guy Lalonde, Peter Schatz, David Tumelty, Balu Palani, Genet Zemede
  • Peptides that bind to the erythropoietin receptor
    Patent number: 7084245
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Grant
    Filed: May 12, 2004
    Date of Patent: August 1, 2006
    Assignee: Affymax, Inc.
    Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
  • Novel peptides that bind to the erythropoietin receptor
    Publication number: 20060040858
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: October 27, 2005
    Publication date: February 23, 2006
    Applicant: Affymax, Inc.
    Inventors: Christopher Holmes, Qun Yin, Guy Lalonde, Peter Schatz, David Tumelty, Balu Palani, Genet Zemede
  • Novel peptides that bind to the erythropoietin receptor
    Publication number: 20050137329
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: May 12, 2004
    Publication date: June 23, 2005
    Applicant: Affymax, Inc.
    Inventors: Christopher Holmes, Qun Yin, Guy Lalonde, Peter Schatz, David Tumelty, Balu Palani, Genet Zemede